A Phase 2/3 interventional study of Pegylated Interferon Alfa-2a and Recombinant Interferon Alfa 2a in Chronic Myelogenous Leukemia, Malignant Melanoma and Renal Cell Carcinoma, sponsored by Hoffmann-La Roche. Completed at 8 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-09.
Sponsored by Hoffmann-La Roche · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Russian Federation — 4 open to participants now, 4 under way, none of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Russian Federation.
Among the 26 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Russian Federation, this one is the 19th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2004, is one of 2 in phase 2/3, and was the 19th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →4 of the 26 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Russian Federation are open now. Recruiting first, the newest first:
St. Petersburg State Pavlov Medical University · Sites in Russian Federation
Ages 18–75
St. Petersburg State Pavlov Medical University · Sites in Russian Federation
Ages 18+
Kartos Therapeutics, Inc. · Sites in Russian Federation, United States, Canada and 5 more countries
Ages 18+
University of Jena · Sites in Russian Federation, Czechia, Germany and 1 more country
Ages 18+
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 8 · Phase 4 1
First in 2004; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 94 across the 22 interventional studies, 432 across the 3 observational. Of the 18 that completed or were terminated, 13 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 26 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 2 studies filed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive — fewer than ten, so there is no comparison to draw.
1 of the studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Russian Federation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06532084St. Petersburg State Pavlov Medical UniversitySorafenib Relapase Prophylaxis After HCT With PTBCy Regimen | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open label extension study will give an opportunity to the participants that have responded to the treatment with Pegylated-Interferon Alfa-2a (Pegasys) or Recombinant Interferon Alfa-2a (Roferon-A®) in prior clinical studies NO15753 (NCT00003542) for Renal Cell Carcinoma (RCC), NO15764 (NCT number not available) and NO16006 (NCT02736721) for Chronic Myelogenous Leukemia (CML), and NO16007 (NCT number not available) for Malignant Melanoma (MM).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who responded to interferon alfa-2A (either pegylated interferon alfa-2A or recombinant interferon alfa 2A) treatment during the parent study will continue to receive the same treatment in this study. Pegylated interferon alfa-2A will be administered subcutaneously once weekly and recombinant interferon alfa 2A will be administered subcutaneously once daily, until disease progression, withdrawal, or death whichever occurs first (up to approximately 3 years).
Drug: Pegylated Interferon Alfa-2a · Drug: Recombinant Interferon Alfa 2a
Participants will maintain the same dose they were receiving in the parent protocol.
Also known as: Pegasys
Participants will maintain the same dose they were receiving in the parent protocol.
Also known as: Roferon-A
Number of Participants With Serious Adverse Events (SAEs)
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship to the study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; Life-threatening experience (immediate risk of dying); Persistent or significant disability or incapacity; and congenital anomaly.
Time frame: Baseline up to approximately 3 years
Number of Participants With Overall Tumor Response
Tumor response was assessed every 6 months using hematological evaluation or any other appropriate diagnostic techniques, as per standard of care practice. The complete response (CR) and partial response (PR) status were recorded from case report form.
Time frame: Baseline until disease progression, withdrawal or death, whichever occurred earlier (assessed every 6 months up to approximately 3 years)
A total of 9 participants were recruited in the study: 8 participants from study NO16006 (NCT02736721) and 1 participant from study NO16007 (NCT number not available).
| Milestone | Interferon Alfa-2A in Cancer Participants |
|---|---|
| Started | 9 |
| Completed | 4 |
| Not completed | 5 |
| Withdrew: Death | 1 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Disease remission | 1 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship to the study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; Life-threatening experience (immediate risk of dying); Persistent or significant disability or incapacity; and congenital anomaly.
| participants | Interferon Alfa-2A in Cancer Participants |
|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 1 |
Tumor response was assessed every 6 months using hematological evaluation or any other appropriate diagnostic techniques, as per standard of care practice. The complete response (CR) and partial response (PR) status were recorded from case report form.
| participants | Interferon Alfa-2A in Cancer Participants |
|---|---|
| CR | 9 |
| PR | 0 |
Collected over Baseline up to approximately 3 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Interferon Alfa-2A in Cancer Participants | — | 1/9 (11.1%) | — |
| Event | Interferon Alfa-2A in Cancer Participants |
|---|---|
| Lung InfectionInfections and infestations | 1/9 |
All participants who were recruited in the study.
| Age, Continuous(years) | Interferon Alfa-2A in Cancer Participants |
|---|---|
| Mean | 48.1 ± 18.3 |
| Gender(Participants) | Interferon Alfa-2A in Cancer Participants |
|---|---|
| Female | 2 |
| Male | 7 |
The record gives a start of Jan 2004, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 8 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Peginterferon alfa-2a · Interferon alpha-2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →